As we close 2025 and enter what we expect to be a defining year for Allogene Therapeutics, Inc., the environment around us is ...
Sickle cell disease—the subject of a new Seminar in The Lancet—is one of the most prevalent and fastest-growing genetic disorders worldwide. Although its true prevalence is difficult to determine ...
Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results